HIMS & HERS Health Shares Rise After CEO’s Remarks

Shares of telehealth company HIMS & HERS Health saw a 12.1% increase in the afternoon session. This surge followed comments from the CEO about the continuation of affordable, combined GLP-1 weight loss drug options. This was in response to the conclusion of its partnership with Novo Nordisk, which previously provided the brand’s weight loss drug, Wegovy. Novo Nordisk ended the collaboration due to concerns regarding the marketing and sales practices of HIMS & HERS’ combined products.

Despite the end of their partnership, the CEO expressed confidence in the availability of budget-friendly alternatives, a sentiment that seems to have resonated well with investors. The weight loss treatment market is sizable, and HIMS & HERS’ approach to offer lower-cost solutions could be important for future growth.

At the end of the trading day, shares closed at $46.28, marking an 11.7% increase from the previous close.

Interestingly, HIMS & HERS Health has experienced considerable volatility, with 94 moves exceeding 5% in the last year. This latest rise indicates a significant shift in how the market perceives the company.

A notable drop occurred just three days prior, when the stock plummeted by 29.2% after Novo Nordisk announced it would terminate its agreement with HIMS & HERS.

This surprising development came just months after their partnership was expanded. Novo Nordisk cited potential violations by HIMS & HERS, claiming they may have engaged in false promotions and sold illegal Wegovy products that could jeopardize patient safety. Losing this collaboration could be quite damaging for HIMS & HERS, as weight loss medications have been a significant contributor to their recent sales growth.

Since the beginning of this year, HIMS & HERS Health has climbed 82.3%, yet the share price currently sits at $45.95, which is 33.2% lower than its 52-week high of $68.74 reached in February 2025.

There’s an interesting thought about younger investors today not necessarily grasping the age-old lessons laid out in classic trading strategies. These principles were established long ago when tech giants like Microsoft and Apple first rose to prominence. If similar strategies are applied today, enterprise software ventures leveraging generative AI could be the next big winners. In that spirit, there could be some valuable insights in an upcoming report regarding profitable and rapidly growing enterprise software stocks poised to harness the future of automation.